Mexiletine in the Treatment of LQT2, LQT3, and Acquired LQTS: A Meta-Analysis
Background: High mortality in patients with Long QT Syndrome (LQTS) can be reduced with proper treatment. Gene-specific therapy is crucial, as many treatments are not equally effective across different LQTS types. While mexiletine has been established in the treatment of LQT3, its use in other type...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Indonesian Heart Association
2025-05-01
|
| Series: | Majalah Kardiologi Indonesia |
| Subjects: | |
| Online Access: | https://ijconline.id/index.php/ijc/article/view/1835 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850151013428756480 |
|---|---|
| author | Dhiya Ihsan Mohammad Iqbal Charlotte Johanna Cool Chaerul Achmad Miftah Pramudyo Hawani Sasmaya Prameswari Mohammad Rizki Akbar |
| author_facet | Dhiya Ihsan Mohammad Iqbal Charlotte Johanna Cool Chaerul Achmad Miftah Pramudyo Hawani Sasmaya Prameswari Mohammad Rizki Akbar |
| author_sort | Dhiya Ihsan |
| collection | DOAJ |
| description |
Background: High mortality in patients with Long QT Syndrome (LQTS) can be reduced with proper treatment. Gene-specific therapy is crucial, as many treatments are not equally effective across different LQTS types. While mexiletine has been established in the treatment of LQT3, its use in other types of LQT need further evaluation.
Methods: A meta-analysis was conducted using systematic electronic searches of PubMed, Embase, and Cochrane Library. We assessed QTc reduction and cardiac events after Mexiletine treatment. Inclusion criteria: any study with no language restriction that diagnoses any type of LQTS, uses mexiletine treatment, and provides QTc comparison before and after treatment. Animal studies were excluded. The NIH Study Quality Assessment Tools and Newcastle-Ottawa Scale were used to evaluate bias. Data were analyzed using Review Manager 5.4 and MedCalc software
Results: Nine studies (n=281) were included. Mexiletine reduced QTc by -64ms (mean difference [MD], -64.22; 95% confidence interval [CI] -76.13 to -52.30; p<.001; I2 60%). Sensitivity and subanalyses showed consistent efficacy. In five studies (n=76), the number of patient with high-risk QTc (>500ms) significantly decreased (Risk Ratio [RR], 0.38; 95% CI 0.26-0.55; p<.001). Five studies (n=141) showed a significant reduction in cardiac events (RR, 0.25; 95% CI 0.14-0.44; p<.001). Two studies reported gastrointestinal (GI) problems and vertigo as side effects of mexiletine treatment.
Conclusion: Mexiletine significantly reduces QTc and cardiac events in LQT2, LQT3, and aLQT patients. Mexiletine also significantly reduces the number of Long QT patients with high-risk QTc
Funding: No external funding was received for this study
Registration: CRD420250652574
|
| format | Article |
| id | doaj-art-9a5dbf46fcdf435e91a154d3b3f0921c |
| institution | OA Journals |
| issn | 0126-3773 2620-4762 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | Indonesian Heart Association |
| record_format | Article |
| series | Majalah Kardiologi Indonesia |
| spelling | doaj-art-9a5dbf46fcdf435e91a154d3b3f0921c2025-08-20T02:26:24ZengIndonesian Heart AssociationMajalah Kardiologi Indonesia0126-37732620-47622025-05-0146110.30701/ijc.1835Mexiletine in the Treatment of LQT2, LQT3, and Acquired LQTS: A Meta-AnalysisDhiya Ihsan0Mohammad Iqbal1Charlotte Johanna Cool2Chaerul Achmad3Miftah Pramudyo4Hawani Sasmaya Prameswari5Mohammad Rizki Akbar6Department of Cardiology and Vascular Medicine, Universitas Padjadjaran – Hasan Sadikin General Hospital, IndonesiaDepartment of Cardiology and Vascular Medicine, Universitas Padjadjaran – Hasan Sadikin General Hospital, IndonesiaDepartment of Cardiology and Vascular Medicine, Universitas Padjadjaran – Hasan Sadikin General Hospital, IndonesiaDepartment of Cardiology and Vascular Medicine, Universitas Padjadjaran – Hasan Sadikin General Hospital, IndonesiaDepartment of Cardiology and Vascular Medicine, Universitas Padjadjaran – Hasan Sadikin General Hospital, IndonesiaDepartment of Cardiology and Vascular Medicine, Universitas Padjadjaran – Hasan Sadikin General Hospital, IndonesiaDepartment of Cardiology and Vascular Medicine, Universitas Padjadjaran – Hasan Sadikin General Hospital, Indonesia Background: High mortality in patients with Long QT Syndrome (LQTS) can be reduced with proper treatment. Gene-specific therapy is crucial, as many treatments are not equally effective across different LQTS types. While mexiletine has been established in the treatment of LQT3, its use in other types of LQT need further evaluation. Methods: A meta-analysis was conducted using systematic electronic searches of PubMed, Embase, and Cochrane Library. We assessed QTc reduction and cardiac events after Mexiletine treatment. Inclusion criteria: any study with no language restriction that diagnoses any type of LQTS, uses mexiletine treatment, and provides QTc comparison before and after treatment. Animal studies were excluded. The NIH Study Quality Assessment Tools and Newcastle-Ottawa Scale were used to evaluate bias. Data were analyzed using Review Manager 5.4 and MedCalc software Results: Nine studies (n=281) were included. Mexiletine reduced QTc by -64ms (mean difference [MD], -64.22; 95% confidence interval [CI] -76.13 to -52.30; p<.001; I2 60%). Sensitivity and subanalyses showed consistent efficacy. In five studies (n=76), the number of patient with high-risk QTc (>500ms) significantly decreased (Risk Ratio [RR], 0.38; 95% CI 0.26-0.55; p<.001). Five studies (n=141) showed a significant reduction in cardiac events (RR, 0.25; 95% CI 0.14-0.44; p<.001). Two studies reported gastrointestinal (GI) problems and vertigo as side effects of mexiletine treatment. Conclusion: Mexiletine significantly reduces QTc and cardiac events in LQT2, LQT3, and aLQT patients. Mexiletine also significantly reduces the number of Long QT patients with high-risk QTc Funding: No external funding was received for this study Registration: CRD420250652574 https://ijconline.id/index.php/ijc/article/view/1835ArrhythmiaElectrocardiographyLong QT syndromeMexiletineQTc |
| spellingShingle | Dhiya Ihsan Mohammad Iqbal Charlotte Johanna Cool Chaerul Achmad Miftah Pramudyo Hawani Sasmaya Prameswari Mohammad Rizki Akbar Mexiletine in the Treatment of LQT2, LQT3, and Acquired LQTS: A Meta-Analysis Majalah Kardiologi Indonesia Arrhythmia Electrocardiography Long QT syndrome Mexiletine QTc |
| title | Mexiletine in the Treatment of LQT2, LQT3, and Acquired LQTS: A Meta-Analysis |
| title_full | Mexiletine in the Treatment of LQT2, LQT3, and Acquired LQTS: A Meta-Analysis |
| title_fullStr | Mexiletine in the Treatment of LQT2, LQT3, and Acquired LQTS: A Meta-Analysis |
| title_full_unstemmed | Mexiletine in the Treatment of LQT2, LQT3, and Acquired LQTS: A Meta-Analysis |
| title_short | Mexiletine in the Treatment of LQT2, LQT3, and Acquired LQTS: A Meta-Analysis |
| title_sort | mexiletine in the treatment of lqt2 lqt3 and acquired lqts a meta analysis |
| topic | Arrhythmia Electrocardiography Long QT syndrome Mexiletine QTc |
| url | https://ijconline.id/index.php/ijc/article/view/1835 |
| work_keys_str_mv | AT dhiyaihsan mexiletineinthetreatmentoflqt2lqt3andacquiredlqtsametaanalysis AT mohammadiqbal mexiletineinthetreatmentoflqt2lqt3andacquiredlqtsametaanalysis AT charlottejohannacool mexiletineinthetreatmentoflqt2lqt3andacquiredlqtsametaanalysis AT chaerulachmad mexiletineinthetreatmentoflqt2lqt3andacquiredlqtsametaanalysis AT miftahpramudyo mexiletineinthetreatmentoflqt2lqt3andacquiredlqtsametaanalysis AT hawanisasmayaprameswari mexiletineinthetreatmentoflqt2lqt3andacquiredlqtsametaanalysis AT mohammadrizkiakbar mexiletineinthetreatmentoflqt2lqt3andacquiredlqtsametaanalysis |